Clinical approval of new prostate cancer class 1 drug of Haichuang pharmaceutical

Recently, "hc-1119", a new drug substance and preparation project independently developed by Chengdu Haichuang Pharmaceutical Co., Ltd (Haichuang pharmaceutical) for the treatment of prostate cancer category 1.1, has officially obtained the approval for clinical trials of drugs issued by the State Food and drug administration The approval of hc-1119 clinical approval document marks another crucial step towards the success of Haichuang's internationally leading new anti-tumor drug independently developed Hc-1119, a new generation of androgen receptor antagonists, is a key drug developed by Haichuang pharmaceutical for the treatment of advanced prostate cancer, which will fill the gap in this field in China The results of preclinical study showed that the pharmacokinetics and pharmacodynamics of the drug were better than those of the same kind of foreign drugs The project has obtained patent authorization from China, the United States, Japan, Europe and other countries and regions Applications from other countries and regions have also entered the stage of substantive examination Among them, the Chinese invention patent has won the silver medal of Chengdu patent award Prostate cancer is the cancer occurring on the prostate epithelium, the most common cancer in men in developed countries The mortality rate is third of the total cancer mortality rate The incidence rate of prostate cancer in the major developed countries is 141 10, with an annual increase of 500 thousand and more than 300 thousand of prostate cancer In recent years, with the prolongation of life expectancy, early detection and popularization, changes in eating habits and carcinogenic factors, the incidence rate of prostate cancer in China has increased rapidly It is estimated that by 2020, there will be 350000 new cases of prostate cancer in China every year Androgen receptor antagonists are the main drugs for the treatment of advanced prostate cancer The annual sales of similar products abroad have exceeded 2 billion US dollars The success of the research and development of hc-1119 will benefit the Chinese people and make the Chinese patients affordable for new drugs Chengdu Haichuang Pharmaceutical Co., Ltd Chengdu Haichuang Pharmaceutical Co., Ltd is a high-tech enterprise dedicated to innovative drug research, founded by a group of overseas experts with experience in R & D and service outsourcing management of top 500 innovative drugs in the world Since its establishment, a professional R & D team led by many experts such as Dr Chen Yuanwei, an expert of the national thousand talents program, has been set up to focus on the R & D and industrialization of new prostate cancer and metabolic diseases The company is located in the "Tianfu life science and Technology Park" of Chengdu high tech Zone, which is the gateway of life science and technology industry in Western China As a national high-tech enterprise, Haichuang pharmaceutical has won the titles of the fourth batch of "key overseas Chinese entrepreneurial teams" of the State Council, the "thousand talents plan" entrepreneurial team of Sichuan Province in 2015, the top innovation and entrepreneurship team of "Chengdu Talent Plan" in 2015, and the talent introduction demonstration unit of Chengdu Chen Yuanwei, general manager of Chengdu Haichuang Pharmaceutical Co., Ltd., vice president of Chengdu Talent Development Promotion Association, expert of national and provincial "thousand talents plan" and "Chengdu Talent Plan", postdoctoral of Lausanne University, Switzerland